BRI collects biological materials to meet the clinical trial management solutions and for its own inventory of bio-products, that is provided to customers, who are involved in research, studies and development. ABRI as well, utilizes the collected bio-products to manufacture quality control products. ABRI works with international collection sites, which enables to identify and collect clinically significant human materials that represent rare and unique disease states. Although the Company specializes in infectious and non-infectious diseases such as HIV, syphilis and allergies, it also serves the market for biological materials for pharmacogenomics, such as: Oncology, cardiology, endocrinology, rheumatology and genetic disorders. Biological materials and the data collected by ABRI are used for the development cycle of in-vitro diagnostic (IVD) test kits, from its initial phase of studies through the final submissions to the U.S. Food and Drug Administration (FDA).